Latest Breaking News On - Digestive oncology - Page 3 : vimarsana.com

SOTIO Biotech: SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab

BASEL, Jan. 19, 2023, a clinical stage immuno-oncology company owned by PPF Group, announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa

Region flamandeKostenloser wertpapierhandelRichard sachseKaren geboesEric van cutsemMichael tattoryRichard kapsaUniversity hospital in leuven belgiumGent university hospital belgiumLifesci communicationsDepartment of gastrointestinalSuperagonist technologyGent university hospitalProfessor karen geboesDigestive oncologyUniversity hospital

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesWenyi weiXbiotech natrunixTrifluridine tipiracilFrench national cancer instituteDepartment of gastroenterologyGeorges francois leclerc cancer centreAmerican cancer societyUniversity hospital dijonMedical centersCome lepageMedical oncologyDigestive oncologyTrue humanTrue human antibodies

XBiotech Inc : XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix Therapy for Colorectal Cancer

INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in FranceAUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE)

United statesWenyi weiXbiotech natrunixTrifluridine tipiracilFrench national cancer instituteDepartment of gastroenterologyGeorges francois leclerc cancer centreAmerican cancer societyUniversity hospital dijonMedical centersCome lepageMedical oncologyDigestive oncologyTrue humanTrue human antibodies

Cantargia AB: Cantargia to host R&D Day on nadunolimab combinational synergy in pancreatic cancer and non-small cell lung cancer

STOCKHOLM, June 9, 2022 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day on Thursday, June 16, 2022 at 09:00 AM EDT (3:00 PM CET), focusing

Region flamandeUnited statesLos angelesSudheer dossPrnewswire cantargiaLuniversidad complutenseLuis pazEric van cutsemVan cutsemUniversity of californiaBelgian foundationUniversity of warsawOncology departmentUniversity hospitals gasthuisbergNational oncology research centerPancreatic cancer action network pan

Cantargia to host R&D Day on nadunolimab combinational synergy in pancreatic cancer and non-small cell lung cancer

/PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day on Thursday, June 16, 2022 at 09:00 AM EDT (3:00 PM.

Region flamandeUnited statesLos angelesSudheer dossLuniversidad complutenseLuis pazEric van cutsemVan cutsemUniversity of californiaBelgian foundationUniversity of warsawOncology departmentUniversity hospitals gasthuisbergNational oncology research centerPancreatic cancer action network panNasdaq stockholm